Pramlintide Research Landscape — Research Reference

Pramlintide functions as a synthetic amylin analog, serving as a valuable tool for researchers investigating the complex interplay of glucose homeostasis, gastric motility, and central nervous system signaling pathways, often explored in conjunction with incretin peptides. Its substantial presence in the scientific literature, evidenced by numerous indexed publications on PubMed and several registered studies on ClinicalTrials.gov, underscores its significance as a subject of extensive research into its distinct physiological modulatory effects.

This reference page compiles an in-depth overview of Pramlintide’s research profile, detailing its fundamental properties, established mechanisms of action in research contexts, and the methodologies employed in its study. It further explores its utility in preclinical models, its comparative research landscape alongside incretin peptides, and prospective avenues for future investigation within the broader field of metabolic and endocrine research.

Pramlintide: A Synthetic Amylin Analog for Research Investigations

Pramlintide stands as a synthetic analog of the naturally occurring human neuroendocrine peptide amylin, co-secreted with insulin from pancreatic beta-cells. In the realm of metabolic research, Pramlintide serves as a pivotal tool for dissecting the complex physiological roles of amylin and exploring its potential modulatory effects on various metabolic pathways. Its unique pharmacological profile, distinct yet complementary to incretin peptides, positions it as an essential compound for investigators seeking to understand glucose homeostasis, gastric emptying kinetics, and central mechanisms governing satiety. The synthetic nature of Pramlintide allows for standardized research applications, enabling reproducible experiments across diverse preclinical models and *in vitro* systems aimed at elucidating fundamental biological principles.

The strategic design of Pramlintide involves minor structural modifications from native amylin, specifically the substitution of alanine for serine at positions 25, 28, and 29. These alterations confer enhanced stability and solubility while preserving critical receptor binding and biological activity, making it a highly reliable and consistent agent for investigative studies. Researchers utilize Pramlintide to probe the direct and indirect impacts of amylin receptor agonism, offering insights into its involvement in postprandial glucose regulation, nutrient absorption, and energy balance. Understanding the precise mechanisms through which Pramlintide exerts its influence is crucial for advancing knowledge in endocrinology and metabolism, fostering a deeper comprehension of peptide-based regulatory systems. For a broader understanding of such compounds, refer to our comprehensive resource on what are research peptides.

The utility of Pramlintide in research extends beyond merely replicating endogenous amylin’s actions; it provides a stable and consistent platform for exploring scenarios where endogenous amylin secretion might be deficient or dysregulated, such as in certain metabolic conditions modeled in preclinical settings. By administering exogenous Pramlintide, researchers can bypass limitations associated with studying fluctuating endogenous peptide levels, thereby isolating the effects of amylin receptor activation. This controlled approach allows for precise dose-response characterization and the investigation of long-term effects on metabolic parameters, including body composition, insulin sensitivity, and hepatic glucose production. Its role as a research compound is instrumental in hypothesis generation and validation regarding the therapeutic potential of amylin receptor agonists in metabolic dysregulation.

Endogenous Amylin Physiology and Pramlintide’s Mechanistic Elucidations

Endogenous amylin, a 37-amino acid peptide hormone, is co-secreted with insulin from pancreatic beta-cells in response to nutrient intake. Physiologically, amylin plays a crucial role in postprandial glucose regulation by several mechanisms, including the suppression of postprandial glucagon secretion, slowing of gastric emptying, and centrally mediated effects on satiety, thereby reducing food intake. These actions collectively contribute to moderating post-meal glucose excursions and promoting overall metabolic homeostasis. The intricate interplay between amylin and other metabolic hormones, such as insulin and glucagon, highlights its significance as a key regulator within the endocrine system, and its deficiency or impaired action can contribute to metabolic imbalances observed in various preclinical models.

Pramlintide, as a synthetic analog, faithfully mimics these physiological actions by acting as an agonist at amylin receptors. The amylin receptor complex is composed of a calcitonin receptor (CTR) and one of three receptor activity-modifying proteins (RAMPs 1, 2, or 3). The specific RAMP co-expressed with the CTR dictates the pharmacological profile and tissue distribution of the receptor, leading to varied physiological responses. Pramlintide’s interaction with these receptor complexes activates intracellular signaling pathways, predominantly involving adenylate cyclase and the production of cyclic AMP (cAMP), which subsequently influences downstream cellular processes integral to its metabolic effects. Understanding these specific receptor interactions and signaling cascades is a major focus of current research using Pramlintide.

Receptor Specificity and Signaling Pathways

The differential expression of RAMPs across various tissues (e.g., brain, stomach, pancreas) contributes to the pleiotropic effects of amylin and Pramlintide. For instance, amylin receptors in the area postrema of the brain are implicated in the anorexigenic and gastric emptying-slowing effects, while those in the pancreas may modulate glucagon secretion. Research utilizing Pramlintide involves detailed pharmacological binding studies and functional assays to characterize its affinity for different amylin receptor subtypes and to elucidate the subsequent activation of intracellular signaling pathways. This includes investigations into G protein coupling, calcium mobilization, and the activation of various kinases, providing a high-resolution view of how Pramlintide transduces its signals within target cells. Such mechanistic clarity is essential for understanding the full scope of Pramlintide’s influence on metabolic control.

Through its potent agonism at amylin receptors, Pramlintide effectively recapitulates the key metabolic actions of endogenous amylin. By slowing gastric emptying, it reduces the rate at which glucose enters the systemic circulation, mitigating postprandial hyperglycemia. Concurrently, its ability to suppress glucagon secretion prevents excessive hepatic glucose production, further contributing to glucose control. The central effects on satiety, mediated through specific neuronal circuits, are critical for appetite regulation and energy intake. Researchers leverage Pramlintide to isolate and investigate these individual components of amylin’s action, providing invaluable insights into the integrated physiological responses to nutrient challenges in preclinical models of metabolic dysfunction.

Research Methodologies for Studying Pramlintide’s Actions

Investigating the multifaceted actions of Pramlintide necessitates a diverse array of research methodologies, spanning from molecular and cellular assays to complex *in vivo* preclinical models. At the cellular level, receptor binding studies are fundamental for characterizing Pramlintide’s affinity and selectivity for amylin receptor subtypes (CTR/RAMP complexes). These experiments often involve radiolabeled Pramlintide or competitive binding assays with unlabeled ligands to determine K_d values and explore receptor occupancy. Functional assays, such as cAMP production measurements or calcium flux assays in cell lines engineered to express specific amylin receptor combinations, provide insights into the immediate downstream signaling events triggered by Pramlintide binding. These *in vitro* approaches are critical for elucidating the direct molecular targets and initiating intracellular cascades.

Beyond isolated cellular systems, *ex vivo* and *in vivo* models are indispensable for understanding Pramlintide’s integrated physiological effects. Isolated organ preparations, such as perfused stomach or pancreas models, allow researchers to study specific tissue responses to Pramlintide, including gastric motility and hormone secretion, independent of systemic influences. For broader metabolic investigations, a range of animal models, particularly rodents (mice and rats), are extensively utilized. These models, often characterized by diet-induced obesity, genetic predispositions to metabolic dysfunction, or chemically induced diabetes, enable the assessment of Pramlintide’s impact on glucose homeostasis, body weight, food intake, and energy expenditure over acute and chronic administration periods. Techniques like glucose tolerance tests (oral and intraperitoneal), insulin sensitivity assessments (e.g., hyperinsulinemic-euglycemic clamps), and metabolic cage studies are standard for evaluating these parameters.

Advanced Techniques in Preclinical Research

Continuous Glucose Monitoring (CGM): Implantation of CGM devices in animal models provides high-resolution, real-time data on blood glucose fluctuations, allowing for detailed analysis of Pramlintide’s effects on postprandial and fasting glucose levels over extended periods.
Gastric Emptying Studies: Techniques such as the acetaminophen absorption test or the use of non-digestible markers (e.g., radioactive isotopes, fluorescent dyes) allow for precise quantification of the rate of gastric emptying, a key action of Pramlintide.
Indirect Calorimetry: Metabolic cages equipped with indirect calorimeters measure oxygen consumption and carbon dioxide production, enabling the calculation of respiratory exchange ratio (RER) and energy expenditure, providing insights into Pramlintide’s effects on whole-body metabolism.
Brain Imaging and Electrophysiology: For central nervous system effects, techniques like fMRI or electrophysiological recordings in specific brain regions can reveal Pramlintide-induced changes in neuronal activity and connectivity related to appetite regulation and satiety signaling.

The robustness of research findings heavily relies on the quality and consistency of the research materials. Ensuring the purity, identity, and potency of Pramlintide is paramount for generating reliable and reproducible data. Researchers often consult Certificate of Analysis (CoA) documents to verify these critical attributes. Furthermore, meticulous experimental design, including appropriate controls, blinding, and statistical power calculations, is essential. The integration of these diverse methodologies provides a comprehensive understanding of Pramlintide’s mechanistic actions, from its molecular interactions to its integrated physiological consequences in complex biological systems, paving the way for further hypothesis generation and targeted investigations in metabolic research.

Pramlintide’s Role in Preclinical Models of Metabolic Regulation

Pramlintide plays a significant role in preclinical research designed to understand and modulate metabolic regulation, particularly in models relevant to diabetes, obesity, and related metabolic syndromes. In various rodent models, Pramlintide has been extensively studied for its ability to improve glucose homeostasis. This includes reducing postprandial glucose excursions, lowering HbA1c equivalents over time, and enhancing insulin sensitivity in models of insulin resistance. Its direct action of slowing gastric emptying is critical in these contexts, as it attenuates the rapid influx of glucose from the gastrointestinal tract, thereby reducing the burden on an often compromised insulin secretion apparatus. Furthermore, the suppression of inappropriate postprandial glucagon secretion, another key effect of Pramlintide, contributes significantly to mitigating hepatic glucose production and maintaining tighter glycemic control.

Beyond glucose regulation, Pramlintide’s impact on body weight and energy balance is a focal point of investigation in preclinical obesity models. Studies consistently demonstrate that chronic administration of Pramlintide can lead to reductions in body weight, primarily through its centrally mediated anorexigenic effects. By acting on specific brain regions, particularly the area postrema and hypothalamus, Pramlintide enhances satiety signals and reduces food intake. This effect is often observed independently of its glucose-lowering actions, highlighting a distinct mechanism through which it influences energy balance. Researchers use Pramlintide to dissect the neural circuits involved in appetite regulation, providing insights into potential targets for modulating feeding behavior and body weight in models of obesity and metabolic excess.

Integrated Metabolic Effects

Metabolic Parameter	Observed Effect in Preclinical Models	Primary Mechanism of Action
Postprandial Glucose	Reduced excursions	Slowed gastric emptying, suppressed glucagon
Fasting Glucose	Often lowered	Improved insulin sensitivity (chronic effect)
Body Weight	Reduced	Decreased food intake (central satiety)
Gastric Emptying	Slowed rate	Direct action on vagal pathways
Glucagon Secretion	Suppressed postprandially	Direct pancreatic and indirect vagal effects
Satiety	Enhanced	Activation of brainstem and hypothalamic pathways

Furthermore, Pramlintide research extends to exploring its potential influence on lipid metabolism and cardiovascular risk factors in preclinical models. While its primary effects are on glucose and weight, indirect benefits on lipid profiles, such as reductions in triglycerides and improvements in cholesterol ratios, have been observed in certain contexts, likely secondary to improved glycemic control and weight loss. Investigating these pleiotropic effects helps in building a more holistic understanding of amylin receptor agonism beyond its immediate and well-characterized actions. The consistency and reliability of Pramlintide as a research compound allows for detailed long-term studies, providing critical data on the sustained impact of amylin agonism in complex metabolic dysregulations, thereby informing future research directions in metabolic science.

Comparative Research: Pramlintide and Incretin Peptide Co-investigations

The field of metabolic research has witnessed significant advancements through the study of incretin peptides, notably Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP). These gut-derived hormones play vital roles in glucose homeostasis, primarily by enhancing glucose-dependent insulin secretion, suppressing glucagon release, and influencing gastric emptying and satiety. Given their complementary yet distinct mechanisms of action compared to Pramlintide, comparative research and co-investigations involving Pramlintide and incretin peptides (or their analogs) represent a particularly fruitful avenue for uncovering synergistic effects and developing more comprehensive strategies for metabolic regulation in preclinical models.

One primary area of comparative research involves examining the individual and combined effects of Pramlintide and GLP-1 receptor agonists. While both classes of peptides influence gastric emptying and satiety, they do so through different receptor systems and potentially distinct neural pathways. Pramlintide’s action on amylin receptors and GLP-1 agonists’ action on GLP-1 receptors can lead to additive or synergistic reductions in postprandial glucose excursions, body weight, and food intake in various preclinical models. Researchers often design experiments to test whether co-administration or the use of multi-agonist peptides (combining amylin and incretin activities) can achieve superior metabolic outcomes compared to monotherapy, especially in models of advanced metabolic dysfunction where single-pathway modulation may be insufficient.

Rationale for Combined Peptide Research

Complementary Mechanisms: Pramlintide modulates glucose through delayed gastric emptying and central satiety, while incretins stimulate glucose-dependent insulin release and have distinct central effects. Combining these targets offers a broader spectrum of action.
Enhanced Efficacy: Preclinical studies suggest that combined amylin and incretin agonism can lead to more pronounced reductions in blood glucose, body weight, and improved lipid profiles compared to individual peptide administration.
Reduced Dosing: In some instances, combining agents may allow for lower doses of each component to achieve desired effects, potentially mitigating off-target effects or optimizing the pharmacological profile in research models.
Addressing Multi-factorial Pathophysiology: Metabolic disorders are multifactorial. Investigating agents that target multiple dysregulated pathways (e.g., insulin secretion, glucagon suppression, gastric emptying, satiety) provides a more holistic approach to research in complex disease models.

Further investigations extend to characterizing the specific intracellular signaling pathways activated by individual peptides versus their combinations. For example, while GLP-1 receptor activation primarily signals through cAMP-PKA pathways, amylin receptor activation also involves cAMP but potentially distinct G protein coupling and downstream effectors. Understanding the cross-talk and potential convergence or divergence of these signaling pathways at a molecular level is crucial. This advanced mechanistic understanding, often achieved through transcriptomic, proteomic, and phosphoproteomic analyses in target tissues, helps to explain the observed physiological synergies and informs the rational design of next-generation peptide-based research compounds. Such rigorous comparative research with Pramlintide and incretin peptides is vital for advancing the understanding of peptide pharmacology and metabolic regulation.

Pharmacokinetic and Pharmacodynamic Considerations in Pramlintide Research

Understanding the pharmacokinetics (PK) and pharmacodynamics (PD) of Pramlintide is fundamental for designing robust and interpretable preclinical research studies. Pharmacokinetics describes how the body handles the research compound—its absorption, distribution, metabolism, and excretion (ADME). For Pramlintide, being a peptide, its PK profile can be influenced by several factors inherent to peptide stability and proteolysis. Administered typically via subcutaneous injection in research models, its absorption rate can vary depending on the injection site, formulation, and species. Researchers must characterize the time to peak plasma concentration (T_max) and the maximum plasma concentration (C_max), as well as the area under the curve (AUC), to inform dosing frequency and extrapolate systemic exposure. Peptide degradation by peptidases in plasma and tissues is a significant consideration, influencing its half-life (t_1/2) and overall duration of action.

Pharmacodynamics, on the other hand, describes the effects of Pramlintide on biological systems and its mechanism of action, particularly the relationship between dose or concentration and the observed physiological responses. For Pramlintide, key PD endpoints include its effects on gastric emptying, glucagon suppression, blood glucose levels, food intake, and body weight in various preclinical models. Establishing comprehensive dose-response curves is paramount to identify the minimum effective dose (MED), optimal dose range, and potential ceiling effects. The onset, magnitude, and duration of these PD effects are critical for correlating systemic exposure to biological outcomes, allowing researchers to infer target engagement and efficacy in their specific experimental setups. The interplay between PK and PD dictates the ultimate utility and effectiveness of Pramlintide in modulating metabolic parameters in research investigations.

Factors Influencing Pramlintide PK/PD

Species-Specific Differences: PK/PD parameters can vary significantly across different research species (e.g., mice, rats, non-human primates) due to differences in metabolism, receptor expression, and physiological responses.
Route of Administration: Subcutaneous (SC) is common, but intravenous (IV) or even direct central nervous system (CNS) administration might be used to isolate specific effects, each impacting absorption and distribution kinetics differently.
Formulation: The excipients, concentration, and pH of the Pramlintide solution can affect its stability, solubility, and ultimately its absorption and degradation rates.
Disease State: The metabolic state of the research animal (e.g., diabetic vs. non-diabetic, obese vs. lean) can alter blood flow, enzyme activity, and receptor sensitivity, thereby influencing both PK and PD.
Dosing Regimen: Acute vs. chronic administration, frequency of dosing (e.g., once daily vs. multiple times daily), and timing relative to feeding can profoundly impact the observed metabolic outcomes.

Accurate measurement of Pramlintide concentrations in biological matrices (plasma, tissue homogenates) is often achieved using sensitive analytical techniques such as liquid chromatography-tandem mass spectrometry (LC-MS/MS) or enzyme-linked immunosorbent assays (ELISAs) specifically developed and validated for the peptide. Similarly, precise measurement of PD endpoints requires meticulous experimental protocols and robust assay validation. These PK/PD investigations not only guide the selection of appropriate doses and dosing schedules for *in vivo* studies but also help interpret observed variability in results across different laboratories or experimental conditions. For optimal handling and to preserve the integrity of the research compound for these critical studies, refer to our guidelines on Pramlintide storage and handling.

Advanced Techniques for Elucidating Pramlintide Signaling Pathways

The elucidation of Pramlintide’s intricate signaling pathways demands the application of advanced research techniques that can provide high-resolution insights into molecular and cellular events. “Omics” technologies have revolutionized this field, enabling comprehensive analyses of gene expression, protein profiles, and metabolic changes in response to Pramlintide administration. Transcriptomics, often employing RNA sequencing (RNA-seq), allows researchers to identify global changes in gene expression patterns in target tissues (e.g., brain, pancreas, stomach) following Pramlintide treatment. This can reveal novel downstream targets, affected cellular processes, and potential regulatory networks. Proteomics, utilizing mass spectrometry, further delves into the actual protein expression levels and post-translational modifications, which are often more directly linked to cellular function than mRNA levels alone. Phosphoproteomics, a subset of proteomics, is particularly useful for mapping activation states of signaling kinases and their substrates, offering a dynamic view of Pramlintide-induced signaling cascades.

Beyond broad omics approaches, targeted molecular techniques are crucial for dissecting specific pathways. Receptor imaging, such as autoradiography with radiolabeled Pramlintide or its analogs, provides precise localization of amylin receptors in tissues and brain regions, informing where Pramlintide’s direct actions occur. For live animal studies, advanced PET (Positron Emission Tomography) or SPECT (Single-Photon Emission Computed Tomography) imaging with novel amylin receptor-specific ligands could offer non-invasive visualization of receptor occupancy and engagement *in vivo*. Moreover, genetically engineered animal models incorporating reporter genes or conditional knockout/knock-in strategies allow for the selective manipulation of specific receptor subunits (e.g., RAMPs) or downstream signaling molecules, enabling researchers to pinpoint the precise molecular players mediating Pramlintide’s effects on glucose homeostasis, gastric emptying, and satiety.

Innovative Approaches to Pathway Dissection

Optogenetics and Chemogenetics: These cutting-edge tools allow for precise, cell-type-specific manipulation of neuronal activity. Researchers can use viral vectors to deliver light-sensitive ion channels (optogenetics) or designer receptors exclusively activated by designer drugs (DREADDs, a form of chemogenetics) into specific neuronal populations implicated in Pramlintide’s central actions. This enables the activation or silencing of these neurons to directly assess their contribution to appetite regulation or glucose control.
Spatial Transcriptomics and Proteomics: Moving beyond bulk tissue analysis, these techniques provide high-resolution spatial information on gene and protein expression within tissue sections, allowing for the identification of cellular niches and local signaling events affected by Pramlintide.
CRISPR/Cas9 Gene Editing: Targeted gene editing in cell lines or animal models can be used to create precise mutations in amylin receptor components or downstream signaling proteins, enabling the study of specific residues or domains critical for Pramlintide binding and signal transduction.
High-Throughput Screening of Receptor Variants: Developing cell lines expressing libraries of amylin receptor variants or RAMP combinations, coupled with high-throughput functional assays, can rapidly identify optimal receptor configurations for specific Pramlintide-mediated responses.

The integration of these advanced techniques allows for a multi-layered understanding of Pramlintide’s actions, from the initial receptor binding event to the ultimate physiological response. By combining global omics data with targeted molecular and cellular manipulations, researchers can build comprehensive maps of Pramlintide’s signaling networks, identify novel targets, and delineate the complex interplay between different pathways. This sophisticated approach to pathway elucidation is critical for maximizing the research utility of Pramlintide and translating mechanistic insights into new hypotheses for metabolic regulation.

Emerging Research Avenues and Future Directions for Pramlintide Studies

The established role of Pramlintide in metabolic research provides a robust foundation for exploring novel and emergent research avenues that extend beyond its well-characterized effects on glucose homeostasis and body weight. Future directions for Pramlintide studies are increasingly focusing on its potential pleiotropic effects and its utility in models of complex multi-system disorders. One significant area of emerging research is the investigation of Pramlintide’s neuroprotective potential. Amylin receptors are expressed in various regions of the brain, and accumulating preclinical evidence suggests a role for amylin signaling in neuronal survival, synaptic plasticity, and even cognitive function. Researchers are now exploring whether Pramlintide, through its amylin agonism, can exert beneficial effects in models of neurodegenerative diseases or cognitive impairment, often linked to metabolic dysfunction, providing an exciting new dimension to amylin research.

Another promising avenue involves exploring Pramlintide’s anti-inflammatory and immunomodulatory properties. Metabolic disorders are frequently accompanied by chronic low-grade inflammation, contributing to disease progression. Preliminary preclinical data hint at amylin’s ability to modulate inflammatory pathways, and thus, Pramlintide could be investigated for its potential to mitigate inflammation in metabolic tissues (e.g., adipose tissue, liver) or even in systemic inflammatory conditions. Such research would involve assessing cytokine profiles, immune cell infiltration, and activation markers in response to Pramlintide administration in relevant inflammatory models. These studies could broaden the understanding of amylin’s role beyond traditional metabolic regulation and open doors to new research hypotheses concerning the interconnectedness of metabolic, neurological, and immunological systems.

Frequently Asked Questions

What is the primary class of peptide that Pramlintide belongs to?

Pramlintide is classified as a synthetic analog of the peptide hormone amylin, a neuroendocrine peptide co-secreted with insulin from pancreatic beta-cells.

How does Pramlintide’s mechanism of action differ from insulin in research models?

While insulin primarily facilitates glucose uptake by peripheral tissues, Pramlintide acts via distinct mechanisms, including modulating gastric emptying, suppressing postprandial glucagon secretion, and influencing satiety centers in the brain, as observed in preclinical studies.

Why is Pramlintide often studied alongside incretin peptides in research?

Pramlintide is frequently co-investigated with incretin peptides (such as GLP-1 analogs) due to their complementary mechanisms in metabolic regulation, offering researchers insights into potential synergistic effects on glucose homeostasis, appetite regulation, and body weight parameters in experimental models.

What types of research models are typically utilized to investigate Pramlintide?

Research into Pramlintide commonly employs a range of *in vitro* systems, including cell lines expressing amylin receptors, and *in vivo* animal models such as rodents (e.g., mice, rats) and sometimes non-human primates, to study its effects on metabolic and neuroendocrine pathways.

What are some key physiological endpoints measured in Pramlintide research?

Researchers commonly measure endpoints such as postprandial glucose excursions, fasting glucose levels, glucagon concentrations, food intake, body weight, gastric emptying rates, and various satiety-related behavioral parameters in preclinical investigations.

Can Pramlintide research inform our understanding of central nervous system involvement in metabolism?

Yes, studies on Pramlintide’s ability to cross the blood-brain barrier in certain models and its interaction with central amylin receptors provide valuable data for understanding the neural circuits involved in appetite regulation, satiety, and metabolic control.

What advanced techniques are employed to investigate Pramlintide’s cellular signaling?

Advanced techniques include receptor binding assays, cellular calcium flux measurements, cAMP assays, signal transduction pathway analysis (e.g., MAPK, Akt), and potentially transcriptomic or proteomic profiling following Pramlintide exposure in cell-based research.

What are some challenges researchers might encounter when studying Pramlintide?

Challenges can include ensuring peptide stability *in vitro* and *in vivo*, accurately measuring its impact on complex physiological systems, accounting for species-specific differences in animal models, and distinguishing its effects from those of endogenous amylin.

Scientific References

All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.